AI in Revenue Cycle Management: Where the ROI Is Real

Of all the places healthcare AI gets pitched, revenue cycle management is the one where the economics are easiest to defend. The work is high-volume, rule-bound, and tied directly to cash. When a tool shortens the gap between care delivered and dollars collected, you can see it in days sales outstanding, in clean-claim rates, and in the headcount needed to run a billing operation. As investors who have sat across the table from a lot of services businesses, we find that refreshing. Most AI claims are hard to verify. RCM claims usually are not.

That said, RCM AI is not one thing, and the returns are uneven. Below is how we think about where the value is real today, where it is emerging, and where the hype still outruns the results.

Coding and Charge Capture: The Clearest Win

Autonomous and assisted medical coding is the function where we see the most consistent ROI. Modern coding tools read clinical documentation and either suggest or assign codes, flagging cases that need human review. The value shows up in two places at once: throughput, because coders handle more charts per hour, and accuracy, because the tool catches missed charges and undercoding that quietly leak revenue.

The reason this works is that coding is a constrained problem with a clear right answer most of the time, and a deep well of historical data to learn from. We are skeptical of vendors promising fully autonomous coding across every specialty; the long tail of complex cases still needs experienced humans. But for high-volume, lower-complexity encounters, the efficiency gains are durable and easy to measure. A practical test we apply: ask what percentage of charts the tool can clear without human touch today, and watch that number over a few quarters. If it is climbing, there is a real engine underneath.

Denials and Prior Authorization: Where the Pain Is

Denials management and prior authorization are where the operational pain is most acute, and where AI is starting to earn its keep. Prior auth in particular is a tax on the whole system: staff spend hours assembling documentation, submitting requests, and chasing status. Tools that auto-populate requests, predict which procedures will require authorization, and surface the specific clinical evidence payers want can compress a multi-day process into something far shorter.

On denials, predictive models that flag claims likely to be rejected before submission, and tools that draft appeals from denial reason codes, reduce both rework and write-offs. We like these use cases because the baseline is so bad that even modest improvement compounds. The caution: payer rules change constantly, and a model trained on last year's behavior degrades quietly. The businesses that win here treat the model as something to maintain, not install.

Eligibility, Scheduling, and the Front End

A surprising amount of revenue leakage starts before a patient is ever seen, with eligibility errors, missing authorizations, and no-shows. AI-assisted eligibility verification and intelligent scheduling, which uses no-show prediction to overbook intelligently and fill gaps, attack revenue at the source. These tools rarely get the headlines, but they are often the cheapest, fastest payback in the whole stack because they prevent problems instead of cleaning them up.

What Separates Results from Slideware

The pattern we see across winners and losers is not about the model. It is about integration and workflow. A coding tool that does not write back into the practice management system creates a swivel-chair problem that eats the time savings. A denials model that floods staff with low-confidence alerts gets ignored within a month. The vendors delivering real ROI have done the unglamorous work of fitting into existing systems and existing staff routines, and they measure themselves on outcomes the CFO already tracks.

We also pay attention to how value is shared. Contingency or outcome-based pricing aligns incentives and is a quiet signal that a vendor believes its own numbers. Flat per-seat software priced as if it were a platform, with vague promises of efficiency, gets more scrutiny from us.

The Kiron Take

Revenue cycle is the part of healthcare AI we would underwrite today, because the returns land in metrics that already exist and that everyone trusts. But we underwrite the operating discipline as much as the technology. The question is never just whether the model is good. It is whether the business has wired that model into real workflows, kept it current as payers move, and tied its own economics to results the customer can see. Where those three things are true, the ROI is real. Where they are not, it is a demo.